https://ogma.newcastle.edu.au/vital/access/ /manager/Index en-au 5 An observational study of the discrediting of COX-2 NSAIDs in Australia: Vioxx or class effect? https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:15671 Wed 11 Apr 2018 14:48:42 AEST ]]> Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:14333 2.7 million exposed individuals. Of the extensively studied drugs (ten or more studies), the highest overall risks were seen with rofecoxib, 1.45 (95% CI 1.33, 1.59), and diclofenac, 1.40 (1.27, 1.55), and the lowest with ibuprofen, 1.18 (1.11, 1.25), and naproxen, 1.09 (1.02, 1.16). In a sub-set of studies, risk was elevated with low doses of rofecoxib, 1.37 (1.20, 1.57), celecoxib, 1.26 (1.09, 1.47), and diclofenac, 1.22 (1.12, 1.33), and rose in each case with higher doses. Ibuprofen risk was seen only with higher doses. Naproxen was risk-neutral at all doses. Of the less studied drugs etoricoxib, 2.05 (1.45, 2.88), etodolac, 1.55 (1.28, 1.87), and indomethacin, 1.30 (1.19, 1.41), had the highest risks. In pair-wise comparisons, etoricoxib had a higher RR than ibuprofen, RRR = 1.68 (99% CI 1.14, 2.49), and naproxen, RRR = 1.75 (1.16, 2.64); etodolac was not significantly different from naproxen and ibuprofen. Naproxen had a significantly lower risk than ibuprofen, RRR = 0.92 (0.87, 0.99). RR estimates were constant with different background risks for cardiovascular disease and rose early in the course of treatment. Conclusions: This review suggests that among widely used NSAIDs, naproxen and low-dose ibuprofen are least likely to increase cardiovascular risk. Diclofenac in doses available without prescription elevates risk. The data for etoricoxib were sparse, but in pair-wise comparisons this drug had a significantly higher RR than naproxen or ibuprofen. Indomethacin is an older, rather toxic drug, and the evidence on cardiovascular risk casts doubt on its continued clinical use.]]> Wed 11 Apr 2018 11:27:22 AEST ]]> Cardiovascular risk and inhibition of cyclooxygenase - a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:1296 Sat 24 Mar 2018 08:32:44 AEDT ]]> Guest authorship, mortality reporting, and integrity in rofecoxib studies (letter) https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:4461 Sat 24 Mar 2018 07:18:29 AEDT ]]>